On January Cover: MAL2 suppresses tumor antigen presentation in breast cancer: buff.ly/2Ler6Vp Xiongbin Lu Yunlong Liu @changlinwan IU School of Medicine #Commentary: buff.ly/3rXoSuH by Devin Dersh & Jonathan Yewdell NIAID News Image credit: Lifei Wang and Xinna Zhang

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients science.sciencemag.org/content/371/65…

We’re excited to announce eight new Mark Foundation ASPIRE awards in six countries: Australia, Canada, Netherlands, USA, and our first in Austria and Switzerland. 94 ASPIRE awards have now been awarded in 11 countries. Read more in this thread: bit.ly/3O0IU0Y

Congrats Xiongbin Lu, Indiana University School of Medicine and Indiana University Melvin and Bren Simon Comprehensive Cancer Center, USA Xiongbin Lu IU School of Medicine bit.ly/3ARRgVI

This work was led by brilliant postdoc Abhinav Achreja from Deepak Nagrath Lab and Tao Yu from Xiongbin Lu lab. It was a great team effort from both labs. Special thanks to reviewers for their incisive reviews and their help in illuminating a critical discovery.

Dr. Mateusz Opyrchal (Mateusz Opyrchal), the Vera Bradley Foundation Scholar in Breast Cancer Discovery at IU Simon Comprehensive Cancer Center and associate professor at IU School of Medicine, shares his research on developing new approaches for metastatic breast cancer. #ResearchCuresCancer #BreastCancerAwarenessMonth

Excited to share my first commentary! Thanks to Xiongbin Lu, @MateuszOpyrchal and Journal of Clinical Investigation JCI - Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression? jci.org/articles/view/…

Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression? buff.ly/3M9tOHi samantha sharma Mateusz Opyrchal & Xiongbin Lu IU School of Medicine highlight miR-155 in relationship between inflammation & cancer; #Commentary